Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

4.99
0.0000
Post-market: 4.98-0.0100-0.20%18:01 EDT
Volume:587.37K
Turnover:2.90M
Market Cap:322.20M
PE:-5.09
High:5.01
Open:5.00
Low:4.86
Close:4.99
52wk High:10.08
52wk Low:3.86
Shares:64.57M
Float Shares:49.21M
Volume Ratio:1.05
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.69
PE(LYR):-3.92

Loading ...

Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 15

Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors

TIPRANKS
·
May 08

Immuneering announces updated data from Phase 2a trial for atebimetinib

TIPRANKS
·
Apr 22

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

GlobeNewswire
·
Apr 22

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)

TIPRANKS
·
Apr 21

Immuneering announces annual shareholder meeting webcast

Reuters
·
Apr 21

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

GlobeNewswire
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Apr 14

Immuneering CEO to join Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 07

Immuneering to present atebimetinib ctDNA analysis at AACR Annual Meeting

Reuters
·
Mar 18

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

GlobeNewswire
·
Mar 18

Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)

TIPRANKS
·
Mar 12

Immuneering price target lowered to $12 from $13 at Piper Sandler

TIPRANKS
·
Mar 09

Immuneering Price Target Maintained With a $11.00/Share by Needham

Dow Jones
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT

Reuters
·
Mar 07

BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners

Reuters
·
Mar 06

BUZZ-U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences

Reuters
·
Mar 06

Shares of Immuneering Down 1.8% Premarket After Q4 Results

THOMSON REUTERS
·
Mar 06

BUZZ-Immuneering rises as quarterly loss comes in below estimates

Reuters
·
Mar 06

Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs

Reuters
·
Mar 06